Closed · PA-06-432 · CFDA 93.242;93.279 · Discretionary

Therapeutics Development for HIV/AIDS-Associated Neuropsychological Disorders (SBIR[R43/R44])

Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.

up to $250K
Award range
Closed
Status
January 7, 2010
Close date
-
Expected awards

The verdict

Therapeutics Development for HIV/AIDS-Associated Neuropsychological Disorders (SBIR[R43/R44]) is a closed discretionary listing from National Institutes of Health that offered Up to $250,000. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.

up to $250K
award range
Closed
application status
93.242;93.279
CFDA program
12,419
other opportunities from National Institutes of Health

Archived opportunity record

Therapeutics Development for HIV/AIDS-Associa… is closed (last close January 7, 2010). Check the agency catalog for replacement NOFOs. National Institutes of Health still indexes 12,419 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed January 7, 2010

Posted May 22 Closes Jan 7

Instrument

Grant

Description

This funding opportunity announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for the development of therapeutics to treat HIV/AIDS-associated mental and neurological disorders. The NIMH Center for Mental Health Research on AIDS (CMHRA) and NIDA encourage the discovery and development of novel agents, methods, biomarkers, and drug delivery technologies that can directly or indirectly eliminate/eradicate HIV reservoirs in the brain. Novel assays/models of neurotoxicity and treatment efficacy measures are invited as are novel in vitro/vivo models that can be used for screening potential therapeutic agents. This FOA also supports studies that examine agents or therapeutic strategies that protect/ameliorate/treat the long-term side effects of antiretroviral agents in the presence or absence of psychotropic medications, drugs of abuse, or medications to treat drug abuse. We additionally encourage the development of adjunctive therapies against the consequences of HIV in the CNS in the context of mental illness or drug addiction. -Budgets up to $250,000 total costs per year and time periods up to 2 years for Phase I may be requested. Budgets up to $450,000 total costs per year and up to 3 years may be requested for Phase II. -No funds have been specifically set aside for this program; the number of awards and the amount of funds provided for awards have not been predetermined. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-06-433 that solicits applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. -Eligible organizations: Only United States SBCs are eligible to submit SBIR applications. A SBC is one that, on the date of award for both Phase I and Phase II funding agreements, meets ALL of the criteria as described in Section III. -Eligible individuals: Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. On an SBIR application, the Project Director/Principal Investigator (PD/PI) must have his/her primary employment (more than 50%) with the SBC at the time of award and for the duration of the project. -Applicant SBCs may submit more than one application, provided each application is scientifically distinct.

Market-open applicant set · includes for-profit door

The eligibility set for Therapeutics Development for HIV/AIDS-Associa… includes a for-profit door among 2 printed types (Small businesses; Others (see official listing text)). Competitive traffic can include commercial applicants alongside other listed classes. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity codes span Education · Health (ED;HL). Only 32 other National Institutes of Health listings share this exact eligibility-code string (0% of 12,420).

Code 23
Small businesses
Code 25
Others (see official listing text)

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV

What to do next

Therapeutics Development for HIV/AIDS-Associa… is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 93.242;93.279 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants